|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administrationFrequency
|
once daily
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:ATCCode
|
A10AE06
|
|
gptkbp:contraindication
|
hypersensitivity to insulin degludec
|
|
gptkbp:drugClass
|
gptkb:long-acting_insulin
|
|
gptkbp:duration
|
over 42 hours
|
|
gptkbp:form
|
solution for injection
100 units/mL
200 units/mL
|
|
gptkbp:genericName
|
gptkb:insulin_degludec
|
|
gptkbp:halfLife
|
25 hours
|
|
gptkbp:indication
|
gptkb:type_2_diabetes
type 1 diabetes
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
regulates glucose metabolism
|
|
gptkbp:penDevice
|
gptkb:FlexTouch
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
https://www.novo-pi.com/tresiba.pdf
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:product
|
recombinant human insulin analog
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
injection site reaction
allergic reaction
|
|
gptkbp:storage
|
2–8°C (refrigerated)
|
|
gptkbp:usedFor
|
gptkb:diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Insulin
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tresiba
|